




4Q FY2025
**FINANCIAL RESULTS
OVERVIEW**





Thank You for Your Attention

Safe Harbor

This presentation contains forward-looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operating cash flow, capital expenditures, net interest and other/expense, impact of acquisitions and related financing, share repurchases, dividends, diluted share counts, and currency exchange rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations. The words "anticipate," "plan," "estimate," "expect," "intend," "will," "should," "forecast," "project" and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to

successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the impact relating to or arising from changes to tariffs, import/export or trade policies; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended July 31, 2025.


The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP measures. Non-GAAP measures exclude charges primarily related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, and net (gain) loss on equity securities. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. With respect to the company's guidance, most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Accordingly, no reconciliation to GAAP amounts has been provided.

Agilent 4Q25 Results

Revenue Beat,
200bps+ Op Margin
expansion vs. Q3,
9% EPS growth



- Revenue \$1.86B, exceeds the high end of guide with accelerating core growth⁽¹⁾ for 6 consecutive quarters
- EPS \$1.59⁽²⁾, +9% YoY
- Operating margin 27.2%⁽²⁾, an increase of 210bps versus last quarter
- Delivered FY25 core growth of 4.9%⁽¹⁾, 140bps better than the high end of initial annual growth guidance



\$545M operating cash flow
\$85M to purchase 0.7M shares
\$93M invested in capex
\$70M in dividends

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.



Broad Growth in Q4 led by LDG

All three segments meet or exceed revenue expectations; LC & LC/MS and CDMO highlight growth momentum

LDG

22.7%
Operating Margin⁽²⁾

+11%

Core Growth⁽¹⁾⁽²⁾
+15% Reported

- Cont'd LC & LC/MS strength
- CDMO (siRNA, GLP-1) drives growth and margins

ACG

32.5%
Operating Margin⁽²⁾

+6%

Core Growth⁽¹⁾⁽²⁾
+7% Reported

- +HSD growth in all regions except China
- Altura bio-inert LC column launch driving strong interest

AMG

24.7%
Operating Margin⁽²⁾

+3%

Core Growth⁽¹⁾⁽²⁾
+4% Reported

- Americas and Europe strong on semi and chemicals & energy investments
- GC & GCMS and CPO driving results

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.



GEOGRAPHY

PRODUCT TYPE

The Americas and Europe benefitting from regionalization of supply chains driving investment

- Americas
42% of Agilent Revenue⁽²⁾
- Europe
28% of Agilent Revenue⁽²⁾
- Asia-Pacific
30% of Agilent Revenue⁽²⁾



(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

(2) % of Q4'25 Agilent revenue.



GEOGRAPHY

PRODUCT TYPE

Q4 revenue mix

Consumables, services, & informatics up 100 bps year-over-year

- Consumables
Services
Informatics
- Instruments

% of total revenue

65%

35%

Q4 REVENUE Strong HSD+ growth in 5 largest end markets

Excellent Pharma growth,
broad strength in Applied
markets and Dx offsets
continued softness in
Acad. & Gov't

Pharma

Continued improvement with a pickup in activity at large US biopharma and excellent CDMO growth

**Q4 Core
Growth⁽¹⁾
Results**

+12%

37%

Academia & Government

NIH/US gov't spending impact continues, while Europe and Asia slow down on more difficult comps

-10%

7%

Diagnostics & Clinical

Durable growth led by our Pathology franchise with particular strength in the Americas and Europe

+7%

15%

Chemicals & Advanced Materials

Americas and Europe drive results, aided by semi re-shoring driving upstream chemicals investments

+7%

22%

Food

Regulation and PFAS investments drive Food strength in the Americas and Europe

+7%

9%

Environmental & Forensics

Commercial and Forensics labs in the Americas activate spending of remaining '25 capex budgets

+9%

10%

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

(2) % of Q4'25 Agilent revenue.

FY26 Initial Guidance⁽¹⁾

Growth and margin expansion driven by Ignite and improving market conditions



\$30M FY26	Net Interest + Other Inc/(Exp)	\$1.6-1.7B FY26	Operating Cash Flow	\$290M FY26	Dividends
---------------	-----------------------------------	--------------------	------------------------	----------------	-----------

14.5% FY26	Tax Rate	\$500M FY26	CapEx	284M FY26	Share Count
---------------	----------	----------------	-------	--------------	----------------

Anti-dilutive
share repurchases
at a minimum⁽³⁾


(1) As of November 24, 2025, based on forecasted currency exchange rates. Presented on a non-GAAP basis.

(2) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(3) The 2024 repurchase program became effective on August 1, 2024 and commenced upon completion of our 2023 repurchase program in September 2025.

1Q26 Guidance⁽¹⁾

Expecting continued strength in Pharma and CAM driven by year-end capital spending




\$8M
Q1
Net Interest +
Other Inc/(Exp)

285M
Q1
Share
Count

(1) As of November 24, 2025, based on forecasted currency exchange rates. Presented on a non-GAAP basis.

(2) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.



Agilent
Trusted Answers



Get in touch
with us



investor_relations@agilent.com



www.investor.agilent.com